Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study

Kavalieris, L.; O’Sullivan, P.J.; Frampton, Chris; Guilford, Parry; Darling, David; Jacobson, Elsie C.; Suttie, J. M.; Raman, Jay D.; Shariat, Shahrokh F.; Lotan, Yair

doi:10.1016/j.juro.2016.12.010

Cited by 92 publications

(66 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It achieved an impressive sensitivity and NPV of 91% and 96% compared with cytology (22% and 87%) for detecting BC in a study comprising 803 patients undergoing surveillance . The test also had a high sensitivity of 86% in Ta low‐grade disease . The application of the Cxbladder Monitor in patients with microhaematuria reduced the number of invasive diagnostic procedures such as cystoscopy and CT scans .…”

Section: Discussionmentioning

confidence: 99%

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

et al. 2017

View full text Add to dashboard Cite

ObjectivesTo evaluate the diagnostic accuracy of the Xpert Bladder Cancer (BC) Monitor, compared with cystoscopy and cytology in the oncological follow-up of non-muscle-invasive bladder cancer (NMIBC). Material and MethodsA total of 140 patients with a history of NMIBC undergoing routine surveillance at our institution were enrolled prospectively in this study (ISRCTN study registry number 37210907). Urine cytology was evaluated according to the Paris classification system. In addition, urinary specimens were analysed using the Xpert BC Monitor, which measures five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) using real-time PCR. Descriptive analysis, diagnostic accuracy including sensitivity, specificity, positive (PPV) and negative predictive value (NPV), receiver-operating characteristic curve, and area under the curve (AUC) were calculated. ResultsThe overall sensitivity (0. ConclusionIn this study, we report for the first time that the Xpert BC Monitor, a new mRNA-based urine test, outperforms cytology with regard to sensitivity and NPV, even in low-grade and pTa tumours, with no reduction of specificity.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

et al. 2017

View full text Add to dashboard Cite

show abstract

“…[29][30][31] On the other hand, the predictive effect of a multiple gene signature has been highlighted. 32,33 In this study, we conducted GSVA to screen the most important Recent studies have revealed the involvement of EMT in the pathogenesis of cancers, including BLCA. 34 Some attribute the distinguishing characteristics between NMIBC and MIBC to differences in EMT-related programming.…”

Section: Discussionmentioning

confidence: 99%

An EMT‐related gene signature for the prognosis of human bladder cancer

Cao

Yuan

et al. 2019

J Cellular Molecular Medi

150

120

View full text Add to dashboard Cite

The transition from non–muscle‐invasive bladder cancer (NMIBC) to muscle‐invasive bladder cancer (MIBC) is detrimental to bladder cancer (BLCA) patients. Here, we aimed to study the underlying mechanism of the subtype transition. Gene set variation analysis (GSVA) revealed the epithelial‐mesenchymal transition (EMT) signalling pathway with the most positive correlation in this transition. Then, we built a LASSO Cox regression model of an EMT‐related gene signature in BLCA. The patients with high risk scores had significantly worse overall survival (OS) and disease‐free survival (DFS) than those with low risk scores. The EMT‐related gene signature also performed favourably in the accuracy of prognosis and in the subtype survival analysis. Univariate and multivariate Cox regression analyses demonstrated that the EMT‐related gene signature, pathological N stage and age were independent prognostic factors for predicting survival in BLCA patients. Furthermore, the predictive nomogram model was able to effectively predict the outcome of BLCA patients by appropriately stratifying the risk score. In conclusion, we developed a novel EMT‐related gene signature that has tumour‐promoting effects, acts as a negative independent prognostic factor and might facilitate personalized counselling and treatment in BLCA.

show abstract

“…This marker panel was designed to optimize sensitivity. While this has improved test performance for this goal with reported sensitivity and NPV of 93 and 97%, respectively, it does come at the cost of a low specificity [34]. Sensitivity reached 95% in recurrent disease with high risk of Prog, and false-negative findings were reported in only 1.5% of cases.…”

Section: Urinary Biomarkers For the Surveillance Of Bladder Cancer Pamentioning

confidence: 99%

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study

Cited by 92 publications

References 19 publications

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

An EMT‐related gene signature for the prognosis of human bladder cancer

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

Contact Info

Product

Resources

About